VTGN
Vistagen Therapeutics, Inc.
$0.5400
0.00%
$21.3M
No data for this timeframe.
Vol
Market Cap$21.3M
Cap SizeNano Cap
Inst. Holders6 funds
Inst. Value$1.5M
Inst. Activity0 buys / 4 sells
SEC Reports5
Recent Activity
Jun 15, 2026
earnings_calendar
VTGN Q4 2026 Earnings After Market Close — 2026-06-15
Jun 9, 2026
SEC
Vistagen announced that its fasedienol clinical program has exceeded ICH E1 minimum safety exposure recommendations, wit
8-K — Impact 4/10
May 19, 2026
SEC
Vistagen appointed Dr. Angel S. Angelov as Chief Medical Officer effective May 18, 2026, with a base salary of $425,000,
8-K — Impact 4/10
May 18, 2026
Insider
Angelov Angel S sold 150,000 shares
Chief Medical Officer @ $0.00 ($0.00)
May 12, 2026
SEC
Vistagen announced preliminary positive safety and exploratory efficacy data from the open-label extension (OLE) of its
8-K — Impact 4/10
Apr 7, 2026
Insider
Tressler Nick B. sold 75,000 shares
Chief Financial Officer @ $0.00 ($0.00)
Apr 7, 2026
Insider
Adler Reid G. sold 18,753 shares
Chief Legal Officer @ $0.00 ($0.00)
Inst.
TWO SIGMA INVESTMENTS, LP — TRIM
195,570 shares ($129.4K)
Price Targets
Historical data — last covering-analyst action Dec 2025. No current recommendation available.
$0.9667 (Dec 2025)
Current $0.5378
Low $0.9000
Median $1.00
High $1.00
3 analysts
$0.9000
$1.00
Analyst Ratings
0Strong Buy
0Buy
7Hold
1Sell
2Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Dec 17, 2025 | William Blair | DOWNGRADE | Outperform → Market Perform |
| Dec 17, 2025 | Maxim Group | DOWNGRADE | Buy → Hold |
| Dec 17, 2025 | Jefferies | DOWNGRADE | Buy → Hold |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.27 | $-0.37 — $-0.17 | 39% YoY | 3 |
| Next Q | $-0.25 ▲ +16.0% | $-0.35 — $-0.17 | 47% YoY | 3 |
| Current FY | $-1.71 | $-1.82 — $-1.59 | -3% YoY | 3 |
| Next FY | $-0.98 ▲ +13.8% | $-1.42 — $-0.68 | 43% YoY | 3 |
Latest Reports
NEUTRAL
8-K
4/10
Vistagen announced that its fasedienol clinical program has exceeded ICH E1 minimum safety exposure recommendations, wit
Jun 9, 2026
NEUTRAL
8-K
4/10
Vistagen appointed Dr. Angel S. Angelov as Chief Medical Officer effective May 18, 2026, with a base salary of $425,000,
May 19, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $1.2M | — |
| TWO SIGMA INVESTMENTS, LP | $129.4K | TRIM |
| RENAISSANCE TECHNOLOGIES LLC | $106.4K | TRIM |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $15.4K | NEW |
| MORGAN STANLEY | $8.4K | TRIM |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 18, 2026 | Angelov Angel | A | $0.00 |
| Apr 7, 2026 | Tressler Nick | A | $0.00 |
| Apr 7, 2026 | Adler Reid | A | $0.00 |
| Apr 7, 2026 | Adler Reid | A | $0.00 |
| Apr 7, 2026 | Cote Elissa | A | $0.00 |
6 institutional holders with $1.5M total value (2,220,204 shares) as of 2025-Q4. Top holders: VANGUARD, TWO, RENAISSANCE. Net selling activity: 4 institutions trimmed/exited vs 0 added.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 1,824,738 | $1.2M | 82.2% | — |
| 2 | TWO SIGMA INVESTMENTS, LP | 195,570 | $129.4K | 8.8% | TRIM -32.4% |
| 3 | RENAISSANCE TECHNOLOGIES LLC | 160,791 | $106.4K | 7.2% | TRIM -61.9% |
| 4 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 23,302 | $15.4K | 1.0% | NEW |
| 5 | MORGAN STANLEY | 12,658 | $8.4K | 0.6% | TRIM -54.0% |
| 6 | BANK OF AMERICA CORP /DE/ | 3,145 | $2.1K | 0.1% | NEAR_EXIT -90.9% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| TWO SIGMA INVESTMENTS, LP | TRIM | 289,409 | 195,570 | -32.4% | $129.4K | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 422,012 | 160,791 | -61.9% | $106.4K | 2025-Q4 |
| MORGAN STANLEY | TRIM | 27,534 | 12,658 | -54.0% | $8.4K | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | NEAR_EXIT | 34,657 | 3,145 | -90.9% | $2.1K | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 40,500 | 422,012 | +942.0% | $1.5M | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | DOUBLED | 89,451 | 289,409 | +223.5% | $1.0M | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 3,378 | 34,657 | +926.0% | $123.0K | 2025-Q3 |
| MORGAN STANLEY | DOUBLED | 12,147 | 27,534 | +126.7% | $97.7K | 2025-Q3 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 24,800 | 40,500 | +63.3% | $81.0K | 2025-Q2 |
| MORGAN STANLEY | NEAR_EXIT | 51,285 | 12,147 | -76.3% | $24.3K | 2025-Q2 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 677 | 3,378 | +399.0% | $6.8K | 2025-Q2 |
| MORGAN STANLEY | DOUBLED | 17,092 | 51,285 | +200.1% | $128.2K | 2025-Q1 |
| UBS Group AG | NEAR_EXIT | 132,314 | 25,779 | -80.5% | $64.4K | 2025-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 83,700 | 24,800 | -70.4% | $62.0K | 2025-Q1 |
| CITADEL ADVISORS LLC | NEAR_EXIT | 65,800 | 10,100 | -84.7% | $25.3K | 2025-Q1 |
| UBS Group AG | DOUBLED | 10,121 | 132,314 | +1207.3% | $390.3K | 2024-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 190,600 | 83,700 | -56.1% | $246.9K | 2024-Q4 |
| CITADEL ADVISORS LLC | NEAR_EXIT | 391,385 | 65,800 | -83.2% | $194.1K | 2024-Q4 |
| MORGAN STANLEY | DOUBLED | 5,319 | 17,092 | +221.3% | $50.4K | 2024-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 23,302 | — | $70.1K | 2024-Q3 |
6 unique insiders with 0 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 18, 2026 | Angelov Angel S | Chief Medical Officer | A | 150,000 | $0.00 | $0.00 |
| Apr 7, 2026 | Tressler Nick B. | Chief Financial Officer | A | 75,000 | $0.00 | $0.00 |
| Apr 7, 2026 | Adler Reid G. | Chief Legal Officer | A | 18,753 | $0.00 | $0.00 |
| Apr 7, 2026 | Adler Reid G. | Chief Legal Officer | A | 56,247 | $0.00 | $0.00 |
| Apr 7, 2026 | Cote Elissa S. | Chief Corp Development Officer | A | 75,000 | $0.00 | $0.00 |
| Apr 7, 2026 | Prince Joshua S. | Chief Operating Officer | A | 18,752 | $0.00 | $0.00 |
| Apr 7, 2026 | Prince Joshua S. | Chief Operating Officer | A | 56,248 | $0.00 | $0.00 |
| Apr 7, 2026 | Singh Shawn | President and CEO | A | 3,732 | $0.00 | $0.00 |
| Apr 7, 2026 | Singh Shawn | President and CEO | A | 71,268 | $0.00 | $0.00 |
5 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 0 mixed, 5 neutral. Avg impact: 3.6/10.
NEUTRAL
8-K
4/10
Vistagen announced that its fasedienol clinical program has exceeded ICH E1 minimum safety exposure
Jun 9, 2026
NEUTRAL
8-K
4/10
Vistagen appointed Dr. Angel S. Angelov as Chief Medical Officer effective May 18, 2026, with a base
May 19, 2026
NEUTRAL
8-K
4/10
Vistagen announced preliminary positive safety and exploratory efficacy data from the open-label ext
May 12, 2026
NEUTRAL
8-K
3/10
Vistagen announced the completion of the last patient visit in the randomized portion of its PALISAD
May 8, 2026
NEUTRAL
8-K
3/10
Vistagen Therapeutics granted stock options to purchase 75,000 shares each to its CEO and other exec
Apr 13, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Historical analyst distribution (last covering-analyst action Dec 2025): 0% buy across 10 analysts — 0 strong buy, 0 buy, 7 hold, 1 sell, 2 strong sell. No current recommendation available.
Analyst Price Targets
Historical data — last covering-analyst action Dec 2025. No current recommendation available.
$0.9667 mean target (Dec 2025)
$0.9000 Low
$1.00 High
| Metric | Value |
|---|---|
| Current Price | $0.5378 |
| Target Low | $0.9000 |
| Target Mean | $0.9667 |
| Target Median | $1.00 |
| Target High | $1.00 |
| # Analysts | 3 |
| Recommendation | — (no recent coverage) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-03-31 |
$-0.27 | $-0.37 | $-0.17 | 38.6% | +0.0% | 2↑ 1↓ | $0.0B | — | 3 |
| Next Q 2026-06-30 |
$-0.25 | $-0.35 | $-0.17 | 46.8% | +16.0% | 2↑ 1↓ | $0.0B | -59.0% | 3 |
| Current FY 2026-03-31 |
$-1.71 | $-1.82 | $-1.59 | -2.6% | +0.0% | 1↑ 1↓ | $0.0B | 110.9% | 3 |
| Next FY 2027-03-31 |
$-0.98 | $-1.42 | $-0.68 | 43.0% | +13.8% | 3↑ 0↓ | $0.0B | -75.6% | 3 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.270 | |
| 7d ago | $-0.270 | |
| 30d ago | $-0.270 | |
| 60d ago | $-0.270 | |
| 90d ago | $-0.270 |
3 analyst firms have rated this stock: 0 upgrades, 3 downgrades, 0 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Dec 17, 2025 | William Blair | DOWNGRADE | Outperform | Market Perform |
| Dec 17, 2025 | Maxim Group | DOWNGRADE | Buy | Hold |
| Dec 17, 2025 | Jefferies | DOWNGRADE | Buy | Hold |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 0 | 0 | 7 | 1 | 2 | 0% | |
| May 1, 2026 | 0 | 0 | 7 | 1 | 2 | 0% | |
| Apr 1, 2026 | 0 | 0 | 7 | 1 | 2 | 0% | |
| Mar 1, 2026 | 0 | 0 | 7 | 1 | 2 | 0% | |
| Feb 1, 2026 | 0 | 0 | 7 | 1 | 2 | 0% | |
| Jan 1, 2026 | 0 | 0 | 7 | 1 | 2 | 0% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 15, 2026
earnings_calendar
VTGN Q4 2026 Earnings After Market Close — 2026-06-15
May 19, 2026
short_volume
Short Volume: VTGN — 55.4% short (0.3M / 0.5M)
Short: 296,584 | Exempt: 0 | TRF Vol: 534,989 | Short Ratio: 55.4% | Off-exchange volume (dark pool + OTC)